Skip to Main Content

In March, as waves of Covid-19 cases began surging across the U.S., biotech venture capitalist Robert Nelsen was “pissed off” about his prescient fear that new biotech treatments, even if they emerged, would not be able to be manufactured in sufficient amounts.

As usual, Nelsen’s rage resulted in a new company: Resilience, backed by $800 million from Nelsen’s ARCH Venture Partners, 8VC, and other sources, and aimed at transforming manufacturing. The company’s board includes a who’s who of former industry and government officials. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • They are not innovating in new products (biologics and vaccines), but it’s not cleare what they will be doing. Is “Resilience” a contract manufacturer that will produce lots of biologics and vaccines for others? Or are they developing new technologies to be better at production than others, and then they license that to other contract manufacturers?

  • I like to flatter myself as a futurist and would love to share some of my thoughts and ideas with Dr Nelsen

Comments are closed.